Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Duke University Medical Center, Durham, NC, United States

Survival: 9.9 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Durham, NC
Hospital: Duke University Medical Center
Journal: Link
Date: 12/2008

Patients: This phase 2 study involved 81 patients with recurrent glioblastoma multiforme. The median age was 52 years, ranging from 29 to 81. The majority (63%) were men.

Treatment: Patients were treated with the biological therapy cilengitide. Cilengitide is a small piece of a protein, called a peptide. There were two different treatment groups, receiving different doses.

Toxicity: Five deaths occurred while patients were taking the study drug or within 28 days after stopping. Four of these were from progressing disease and one from aspiration pneumonia. Four patients experienced grade 3 toxicities: transaminase elevation, arthralgia, weight gain and headache. One grade 2 intracranial hemorrhage was reported in a patient with progressive disease.

Results: The median overall survival was 9.9 months for patients receiving the higher dose of cilengitide, and 6.5 months for those receiving the lower dose.

Support: This study was supported by Merck KGaA and EMD pharmaceuticals, which developed Cilengitide.

Correspondence: Dr. David A. Reardon

E-mail to a Friend Email Physician More Information